科研之友
微信
新浪微博
Facebook
分享链接
摘要
Activating macrophages for cancer immunotherapy has attracted intensive attention in recent years, but faces two major challenges. First, tumor-associated macrophages (TAMs) are predominately pro-tumori-genic M2 phenotype. Second, the phagocytosis of macrophages to cancer cells is severely inhibited by the upregulation of 'don't eat me' signals. In this study, we identified that resiquimod (R848), a small-molecule toll-like receptor 7/8 agonist, could promote the phagocytosis of macrophages while reprogramming macrophages to the anti-tumoral M1 phenotype. This pro-phagocytic effect could be further improved via the combination with anti-SIRP alpha antibody (aSIRP alpha). We then constructed a disulfide-bridged mesoporous silica nanoparticle (MSN)-based delivery system (RMSN-aSIRP alpha) for the co-delivery of R848 and aSIRP alpha to potentiate macrophage-mediated cancer immunotherapy. RMSN-aSIRP alpha was prepared by loading R848 into the cavity, and adsorbing aSIRP alpha on the surface of MSNs. aSIRP alpha interacts with SIRP alpha on macrophages to block the CD47-SIRP alpha axis, and synergized with R848 to promote macrophage phagocytosis. Meanwhile, R848 stimulated M2-to-M1 repolarization of TAMs in the tumor microenvironment (TME). In animal stu-dies with aggressive melanoma and breast cancer models, RMSN-aSIRP alpha significantly improved the anti-tumor efficacy and resulted in immunostimulatory TME by reducing the abundance of M2 macrophages and facilitating tumor infiltration of CD8+ T cells. These findings demonstrate that the nanoparticle-enabled combination of macrophage repolarization and CD47-SIRP alpha blockade can amplify macrophage-based immune response.
